Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037) a randomised, controlled, open-label, phase 3 trial》.pdfVIP

Articles Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeff rey S Weber, Sandra P D’Angelo, David Minor, F Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Hoeller, Nikhil I Khushalani, Wilson H Miller Jr, Christopher D Lao, Gerald P Linette, Luc Thomas, Paul Lorigan, Kenneth F Grossmann, Jessica C Hassel, Michele Maio, Mario Sznol, Paolo A Ascierto, Peter Mohr, Bartosz Chmielowski, Alan Bryce, Inge M Svane, Jean-Jacques Grob, Angela M Krackhardt, Christine Horak, Alexandre Lambert, Arvin S Yang, James Larkin Summary Background Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses Lancet Oncol 2015; 16: 375–84 in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors. We assessed the efficacy and Published Online safety of nivolumab compared with investigator’s choice of chemotherapy (ICC) as a second-line or later-line treatment March 18, 2015 in patients with advanced melanoma. /10.1016/ S1470-2045(15)70076-8 See Comment page 350 Methods In this randomised, controlled, open-label, phase 3 trial, we recruited patients